Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill.

Dec 17, 2025 · Semaglutide mildly shifted some CSF AD biomarkers, although the drug is not expected to reduce amyloid. Some scientists believe semaglutide could prevent AD or other dementias, if …

Dec 17, 2025 · Background NT-0796 is an oral, brain-penetrant inhibitor of inflammasomes that contain NLRP3, aka nod-like receptor family pyrin domain-containing protein 3. Inflammasomes are …

Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies …

Oct 23, 2025 · NLRP3 inhibitor must pass into brain to effect weight loss in obese mice. The inhibitor calms microgliosis in the hypothalamus, raising hopes for such effects in other brain areas. TN-783 …

Dec 1, 2023 · Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. …

Rubin R. Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331 (18):1519-1521. PubMed.

Scheltens P, Atri A, Feldman H, Hansson O, Knop F, Sano M, Dethlefsen C, Johannsen P, León T, Hansen CT, Cummings J. Baseline Characteristics from Evoke and Evoke+: Two Phase 3 …

Nov 25, 2025 · A large proteogenomic study identified 49 pQTLs, in either CSF or plasma, linked to cerebral small vessel disease. Immune and ECM proteins predominated.

Zhang L, Zhang L, Li L, Hölscher C. Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease. J Parkinsons Dis. 2019;9 (1):157-171.